860642-35-9

Usage

Uses

Used in Pharmaceutical Synthesis:
1-(4-Fluoro-phenyl)-but-3-en-2-one is used as a key intermediate in the pharmaceutical industry for the synthesis of various drugs and organic compounds. Its unique chemical structure allows for the creation of a diverse range of medicinal products.
Used in Flavoring Agents:
In the food industry, 1-(4-Fluoro-phenyl)-but-3-en-2-one is used as a flavoring agent due to its strong odor. This application enhances the taste and aroma of various food products, contributing to a more enjoyable consumer experience.
Used in Dye and Perfume Manufacturing:
This chemical compound is also utilized in the manufacturing of dyes, perfumes, and other aromatic chemicals. Its distinctive scent and color properties make it a valuable ingredient in these industries, allowing for the creation of a wide array of products with unique and appealing characteristics.
Used in Anti-Inflammatory and Anti-Cancer Research:
1-(4-Fluoro-phenyl)-but-3-en-2-one has been studied for its potential biological activities, including its possible roles as an anti-inflammatory and anti-cancer agent. This research could lead to the development of new treatments for various inflammatory conditions and cancer types, offering new hope for patients and healthcare providers.

Upstream product

• 459-04-1 4-Fluorophenylacetyl chloride 
• 457948-95-7 2-(4-fluorophenyl)-N-methoxy-N-methylacetamide 
• 3536-96-7 vinylmagnesium chloride 
• 405-50-5 p-Fluorophenylacetic acid 
• 1826-67-1 vinyl magnesium bromide 

Downstream Products

• 920025-44-1 C₂₀H₃₁FO₇S₂ 
• 920025-45-2 C₃₀H₃₇F₇O₇S₂ 
• 920025-40-7 C₄₀H₆₃FO₅Si 
• 920025-41-8 C₃₄H₄₉FO₅ 
• 920025-43-0 C₁₄H₁₉FO₃ 
• 860642-36-0 tert-butyl{[1-(4-fluorobenzylidene)prop-2-en-1-yl]oxy}-dimethylsilane 

Relevant academic research and scientific papers

Organocatalytic Stereoconvergent Synthesis of α-CF3 Amides: Triketopiperazines and Their Heterocyclic Metamorphosis

The highly enantioselective alkylation of α-CF3 enolates, generated from triketopiperazines, has been accomplished through use of a bifunctional thiourea organocatalyst to facilitate 1,4-addition to varied enone acceptors. On treatment with appropriate nitrogen nucleophiles, the chiral triketopiperazine products undergo a metamorphosis, to provide novel fused heterocyclic lactams such as extended pyrazolopyrimidines.

Use of NK-1 receptor antagonists in pruritus

The invention relates to methods for treating pruritus with an NK-1 receptor antagonist. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonist.

Potent, brain-penetrant, hydroisoindoline-based human neurokinin-1 receptor antagonists

3-[(3aR,4R,5S,7aS)-5-{(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy} -4-(4-fluorophenyl)octahydro-2H-isoindol-2-yl]-cyclopent-2-en-1-one (17) is a high affinity, brain-penetrant, hydroisoindoline-based neurokinin-1 (NK1) receptor antagonist with a long ce

POLYMORPHS OF A HYDROISOINDOLINE TACHYKININ RECEPTOR ANTAGONIST

This application is directed to a novel polymorph of a hydroisoindoline tachykinin receptor antagonist having the following structural formula A.

Process for making hydroisoindoline tachykinin receptor antagonists

The present invention is directed to a process for preparing certain hydroisoindoline compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The compounds are useful in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety.

HYDROISOINDOLINE TACHYKININ RECEPTOR ANTAGONISTS

The present invention is directed to certain hydroisoindoline compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulati

Hydroisoindoline tachykinin receptor antagonists

The present invention is directed to certain hydroisoindoline compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulati